Patents by Inventor Chengzhi Zhang

Chengzhi Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PHARMACEUTICAL FORMULATIONS
    Publication number: 20210322308
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: January 12, 2021
    Publication date: October 21, 2021
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • DEUTERATED MGL-3196 COMPOUND AND USE THEREOF
    Publication number: 20210292304
    Abstract: Disclosed are a compound as shown in formula (I) or optical isomers, pharmaceutically acceptable salts, prodrugs, hydrates or solvates thereof, wherein R1-R10 are independently selected from H and D, respectively, and not all are H. Compared to the undeuterated control compound MGL3 196, the compound of formula (I) or the optical isomers, pharmaceutically acceptable salts, prodrugs, hydrates or solvates thereof has/have better agonistic activity on thyroid hormone receptor p (THR-p), has/have a longer half-life and a lower clearance rate, has/have better metabolic stability and pharmacokinetic properties, and has/have excellent application prospects in the preparation of THR-p agonists and drugs for treating indications to which THR-p agonists are applicable, including dyslipidemia, hypercholesterolemia, nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).
    Type: Application
    Filed: June 21, 2019
    Publication date: September 23, 2021
    Inventors: Wu DU, Yu LI, Haibo LI, Yuanwei CHEN, Chengzhi ZHANG, Xinghai LI
  • Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
    Publication number: 20210244723
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: March 25, 2021
    Publication date: August 12, 2021
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • NOVEL PHARMACEUTICAL FORMULATIONS
    Publication number: 20210205214
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: March 3, 2021
    Publication date: July 8, 2021
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
    Patent number: 11033540
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: June 15, 2021
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • Pharmaceutical formulations
    Patent number: 10966922
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: April 6, 2021
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury
  • METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS
    Publication number: 20200347008
    Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.
    Type: Application
    Filed: April 15, 2020
    Publication date: November 5, 2020
    Inventor: Chengzhi Zhang
  • METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS
    Publication number: 20200331846
    Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.
    Type: Application
    Filed: November 12, 2019
    Publication date: October 22, 2020
    Inventor: Chengzhi Zhang
  • Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds
    Publication number: 20200290992
    Abstract: Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.
    Type: Application
    Filed: April 20, 2020
    Publication date: September 17, 2020
    Inventor: Chengzhi ZHANG
  • Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
    Publication number: 20200289498
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: November 13, 2019
    Publication date: September 17, 2020
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2
    Publication number: 20200253952
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Charles Arthur, Margaret Bradbury, Thomas George Gant, Manouchehr Shahbaz
  • Dimethoxyphenyl inhibitors of vesicular monoamine transporter 2
    Patent number: 10722479
    Abstract: Described are dimethoxyphenyl inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: July 28, 2020
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Chengzhi Zhang
  • Cyclopropane carboxamide modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 10689370
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 23, 2020
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventors: Chengzhi Zhang, Justin Chakma
  • BENZOQUINOLONE INHIBITORS OF VMAT2
    Publication number: 20200165240
    Abstract: The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 27, 2019
    Publication date: May 28, 2020
    Inventors: Andreas Sommer, Chengzhi Zhang
  • Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds
    Patent number: 10626105
    Abstract: Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: April 21, 2020
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Chengzhi Zhang
  • Aminopyrimidine inhibitors of tyrosine kinase
    Patent number: 10568965
    Abstract: The present invention relates to new aminopyrimidine inhibitors of tyrosine kinase activity, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: February 25, 2020
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventor: Chengzhi Zhang
  • ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE
    Publication number: 20200016148
    Abstract: The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 16, 2020
    Inventors: Chengzhi Zhang, Jim Kerr
  • BENZOQUINOLONE INHIBITORS OF VMAT2
    Publication number: 20200000794
    Abstract: The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: September 12, 2019
    Publication date: January 2, 2020
    Inventors: Thomas G. Gant, Manouchehr Shahbaz, Chengzhi Zhang
  • Methods of manufacturing benzoquinoline compounds
    Patent number: 10513488
    Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 24, 2019
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Chengzhi Zhang
  • Dihydroxyphenyl Neurotransmitter Compounds, Compositions And Methods
    Publication number: 20190374642
    Abstract: The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: August 1, 2019
    Publication date: December 12, 2019
    Inventors: David S. Goldstein, Courtney Holmes, Rudolf-Giesbert Alken, Frank Schneider, Chengzhi Zhang